Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 4, 1998, Pages 315-320

  Louisirirotchanakul, S ^a   Beddows, S ^a   Cheingsong Popov, R ^a   Shaffer, N ^b,c   Mastro, T D ^b,c   Auewarakul, P ^d   Likanonsakul, S ^e   Wasi, C ^b   Weber, J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b HIV/AIDS Collaboration   (Thailand)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Bamrasnaradura Infectious Disease Institute   (Thailand)

Author keywords

Binding and neutralizing; HIV 1 antibody; Subtype specific; Subtypes B and E

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING SITE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SERODIAGNOSIS; SEROTYPE; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

EID: 0032400920     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199812010-00001     Document Type: Article

References (25)

1. Osmanov S, Heyward WL, Esparza J. The WHO Network for HIV isolation and characterization: summary of a pilot study. AIDS Res Hum Retroviruses 1994;10:1325-43.
2. Ou C, Takebe Y, Luo C, et al. Wide distribution of two subtypes of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1471-2.
3. McCutchan FE, Hegerich PA, Brennan TP, et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1887-95.
4. Subbarao S, Limpakarnjanarat K, Mastro TD, et al. HIV-1 in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity. AIDS Res Hum Retroviruses 1997;14:319-27.
5. Kalish ML, Luo C, Weniger BG, et al. Early HIV type 1 strains in Thailand were not responsible for the current epidemic. AIDS Res Hum Retroviruses 1994;10:1573-5.
6. Kalish ML, Baldwin A, Raktham S, et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS 1995;9:851-7.
7. Pau C, Lee Thomas S, Auwanit W, et al. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993;7:337-40.
8. Cheingsong-Popov R, Lister S, Callow D, et al. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10:1379-86.
9. Moore JP, Cao Y, Leu J, et al. Inter- and intraclade neutralization of HIV-1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70:427-44.
10. Mascola JR, Louder MK, Surman SR, et al. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996;12:1319-28.
11. Weber J, Fenyo EM, Beddows S, et al. Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtypes. J Virol 1996;70:7827-32.
12. Auewarakul P, Louisirirotchanakul S, Sutthent R, et al. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env genetic subtype B and E viruses in Thailand. Virol Immunol 1996;9:175-85.
13. Nyambi PN, Nkengasong J, Lewi P, et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996;70:6235-43.
14. Porter KR, Mascola JR, Hupudio H, et al. Genetic, antigenic, serologic characterization of human immunodeficiency virus type 1 from Indonesia. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:1-6.
15. Wasi C, Herring B, Raktham S, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-9.
16. Delwart EL, Shpaer EG, McCutchan FE, et al. Genetic relationships determined by a heteroduplex mobility assay: analysis of HIV env genes. Science 1993;262:1257-61.
17. Moore JP. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to sCD4 by ELISA: HIV-2 has a 25-fold lower affinity than HIV-1 for sCD4. AIDS 1990;3:297-305.
18. De Wolf F, Hogervorst E, Goudsmit J, et al. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10:1387-1400.
19. Bobkov A, Cheingsong-Popov R, Karasyova N, et al. Sequence analysis of the glycoprotein 120 coding region of a new human immunodeficiency virus type 1 subtype G strain from Russia. AIDS Res Hum Retroviruses 1996;12:1385-8.
20. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, et al. Neutralization of primary and T-cell line adapted isolates of the human immunodeficiency virus type 1: role of V3 specific antibodies. J Gen Virol 1998;79:77-82.
21. rgp120 HIV-1 vaccine (VAXGEN/GENETECH) in injecting drug users (IDUs) in Bangkok, Thailand [abstract D(P)045]. Presented at the 4th International Congress on AIDS in Asia and the Pacific, Manila, Philippines, 1997.
22. Girard M, Yue L, Barre-Sinoussi F, et al. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J Virol 1996;70:8229-33.
23. Moore JP, McCutchan FE, Poon S, et al. Exploration of antigenic variation in gp120 from Clades A through F of HIV-1 by using monoclonal antibodies. J Virol 1994;68:8350-64.
24. Sawyer LSW, Wrin MT, Crawford-Miksza L, et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994; 68:1342-9.
25. Bou-Habib DC, Roderiquez G, Oravecz T, et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-13.